Financial Gravity Asset Management, Inc. Exelixis, Inc. Transaction History

Financial Gravity Asset Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$20.17 - $23.93 $40 - $47	2 New	2 $43,000
Q3 2022 Nov 03, 2022	BUY	$15.68 - $22.27 $4,014 - $5,701	256 New	256 $1.97 Million
Q4 2019 Feb 28, 2020	SELL	$15.15 - $18.89 $7,468 - $9,312	-493 Closed	0 $0
Q3 2019 Oct 15, 2019	SELL	$17.68 - $22.65 $12,535 - $16,058	-709 Reduced 58.99%	493 $9,000
Q2 2019 Jul 26, 2019	BUY	$18.93 - $24.75 $22,734 - $29,724	1,201 Added 120100.0%	1,202 $26,000
Q1 2019 Apr 19, 2019	BUY	$19.6 - $24.76 $19 - $24	1 New	1 $0

509

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.